Use of β-lactam/β-lactamase inhibitor combinations to treat nosocomial pneumonia

Infectious Diseases in Clinical Practice

Volumn 11, Issue SUPPL. 1, 2002, Pages

  Suwangool, Panpit ^a  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFOPERAZONE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; IMIPENEM; METICILLIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULPERAZON; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; GRAM NEGATIVE BACTERIUM; HEALTH CARE COST; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; MORBIDITY; MORTALITY; PNEUMONIA; PRACTICE GUIDELINE; REVIEW; RISK FACTOR;

EID: 0036076879     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-200202001-00005     Document Type: Review

References (26)

1. Preventing nosocomial pneumonia: State of the art and perspectives for the 1990s
2. Nosocomial pneumonia in ventilated patients: A cohort study evaluating attributable mortality and hospital stay
3. Nosocomial pneumonia and mortality among patients in intensive care units
4. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies
5. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2
6. Editorial response: Epidemiology of extended spectrum β-lactamases
7. Detection of nosocomial lung infection in ventilated patients: Use of a protected specimen brush and quantitative culture techniques in 147 patients
8. Ventilator-associated bacterial pneumonia: Challenges in diagnosis, treatment, and prevention
9. Antibiotic resistance among gram-negative nosocomial pathogens in the intensive care unit: Results of a 6-year body-site monitoring
10. β-lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone
11. The evolution of resistance to cephalosporins
12. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1990-May 1999, Issued June 1999
13. Preliminary survey of β-lactamase in Thailand
14. Nosocomial pneumonia in the ICU-year 2000 and beyond
15. Transitional antibiotic therapy
16. Switch therapy with β-lactam/β-lactamase inhibitors in patients with community-acquired pneumonia
17. Nosocomial pneumonia. A multivariate analysis of risk and prognosis
18. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients
19. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients
20. Characterization of SFO-1, a plasmid-mediated inducible class β-lactamase from Enterobacter cloacae
21. Clinical evaluation of sultamicillin in lower respiratory tract infections
22. A comparison of ampicillin/sulbactam versus cefotaxime in the therapy of lower respiratory tract infections in hospitalised patients
23. Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotics against clinically important bacteria
24. Treatment of nosocomial pneumonia with cefoperazone/sulbactam
25. Sulbactam/cefoperazone versus cefotaxime for the treatment of moderate-to-severe bacterial infections: Results of a randomized, controlled clinical trial
26. An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients